Trials


Drug Class Indication  Phase SubjectsSites
ACE Inhibitor +Cardioprotective AgentHypertension and Type 2 Diabetes Phase 2 160 12
AntibioticSkin Infections and Bacteremia in Renal ImpairmentPhase 492 10
Anti-thrombotic CAD 10
Cardio and Renal Protective Agent Percutaneous Coronary Intervention/Acute Kidney InjuryPhase 2 361 30
Cardioprotective AgentCABGPhase 3 3025 139
Cardioprotective Agent CABG Phase 2/3 902 42
Cardioprotective Agent Cognitive Deficits Phase 2 400 41
Cardioprotective Agent PCI Phase 2 60 4
Cardioprotective agent Percutaneous Coronary Intervention Phase 2a 120 6
Cholesterol lowering agent High Risk Acute Coronary Syndrome Phase 3 80 8
GPIIb/IIIa Inhibitor Percutaneous Coronary Intervention Phase 2 675 13
Heptagonist (Heparin Reversal Agent) Percutaneous Coronary Intervention Phase 2 17 10
Hormone Male Contraceptive Phase 2 321 10
Insulin Sensitizer Type 2 Diabetes Phase 2 40 3
Insulin Sensitizer Type 2 Diabetes Phase 2 20 1
Insulin Sensitizer Type 2 Diabetes Phase 2 64 12
Kallikrein inhibitorCABG Phase 2 300 38
Kallikrein inhibitor CABG Phase 2 344 35
Nitroxyl (HNO) DonorCongestive Heart Failure Phase 1/2 36 6
Stent (Device Trial)Abdominal Aortic Aneurysm Phase 2 275 45
Thrombin receptor antagonist Non-ST –segment Elevation Acute Coronary Syndrome Phase 310010
MC-1Tardive DyskinesiaPhase 2535